dabigatran has been researched along with phenprocoumon in 23 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (phenprocoumon) | Trials (phenprocoumon) | Recent Studies (post-2010) (phenprocoumon) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 989 | 124 | 210 |
| Protein | Taxonomy | dabigatran (IC50) | phenprocoumon (IC50) |
|---|---|---|---|
| Protease | Human immunodeficiency virus 1 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 22 (95.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Einecke, D | 1 |
| Stiefelhagen, P | 1 |
| Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
| Gliem, M; Hartung, HP; Hermsen, D; Jander, S; van Rooijen, N | 1 |
| Klein, HH | 1 |
| Braun, G; Messmann, H | 1 |
| Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM | 1 |
| Breithardt, G; Deuster, O; Ferner, M; Konrad, T; Meinertz, T; Münzel, T; Rostock, T; Seibert-Grafe, M; von Bardeleben, S; Wachtlin, D | 1 |
| Fiedler, AK; Kastrati, A; Martischnig, AM; Massberg, S; Mayer, K; Mehilli, J; Petzold, T; Pollak, J; Sarafoff, N; Schulz-Schüpke, S; Sibbing, D | 1 |
| Heeger, CH; Kuck, KH; Lemes, C; Lin, T; Mathew, S; Metzner, A; Ouyang, F; Plesman, J; Rillig, A; Tilz, RR; Wissner, E; Wohlmuth, P | 1 |
| Beney, J; Bochatay, L; Jordan-von Gunten, V; Petignat, PA; Roulet, L | 1 |
| Dahmen, A; Gorr, E; Hoppe, C; Horlitz, M; Keskin, K; Koektuerk, B; Schoett, M; Turan, CH; Turan, RG; Yang, A; Yorgun, H | 1 |
| Bluecher, A; Ferreirós, N; Harder, S; Labocha, S; Meyer Dos Santos, IM; Meyer Dos Santos, S; Picard-Willems, B; Singer, OC | 1 |
| Andreas, M; Angleitner, P; Haberl, T; Laufer, G; Moayedifar, R; Riebandt, J; Schima, H; Schlöglhofer, T; Wiedemann, D; Wieselthaler, G; Wolzt, M; Zimpfer, D | 1 |
| Bellmann, B; Landmesser, U; Lenz, K; Lin, T; Lsharaf, AK; Nagel, P; Rillig, A; Roser, M; Tscholl, V | 1 |
| Boulouis, G; Charidimou, A; Goldstein, JN; Gurol, ME; Morotti, A; Pasi, M | 1 |
| Basic, E; Hohmann, C; Hohnloser, SH; Nabauer, M | 1 |
| Ay, C; Königsbrügge, O; Pabinger, I; Quehenberger, P; Weigel, G | 1 |
| Krug, K; Laux, G; Peters-Klimm, F; Schwill, S; Szecsenyi, J; van Lieshout, J; Wensing, M | 1 |
| Baldus, S; Hohmann, C; Hohnloser, SH; Jacob, J; Pfister, R; Walker, J | 1 |
3 review(s) available for dabigatran and phenprocoumon
| Article | Year |
|---|---|
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Gastrointestinal bleeding in cardiological patients].
Topics: Algorithms; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Metabolic Clearance Rate; Morpholines; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Transfusion; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.
Topics: Anticoagulants; Antithrombins; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Hematoma; Humans; Mortality; Odds Ratio; Phenprocoumon; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Thiazoles; Vitamin K; Warfarin | 2018 |
5 trial(s) available for dabigatran and phenprocoumon
| Article | Year |
|---|---|
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Topics: Adult; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Point-of-Care Systems; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Appendage; Atrial Fibrillation; Dabigatran; Echocardiography, Transesophageal; Humans; Phenprocoumon; Prospective Studies; Research Design; Thrombosis | 2016 |
Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
Topics: Adenosine Diphosphate; Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Dabigatran; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation; Ticlopidine | 2015 |
Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial.
Topics: Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Equipment Failure; Female; Follow-Up Studies; Heart Ventricles; Heart-Assist Devices; Humans; Male; Middle Aged; Phenprocoumon; Pilot Projects; Prospective Studies; Thromboembolism; Time Factors; United States; Vitamin K | 2017 |
15 other study(ies) available for dabigatran and phenprocoumon
| Article | Year |
|---|---|
[Stroke prevention in atrial fibrillation. Marcumar alternative in sight].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Phenprocoumon; Pyridines; Randomized Controlled Trials as Topic; Stroke; Vitamin K | 2009 |
[Is the era from the end of warfarin?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Blood Coagulation; Brain Ischemia; Cerebral Hemorrhage; Dabigatran; Disease Models, Animal; Intracranial Embolism; Macrophages; Male; Mice; Mice, Inbred C57BL; Phenprocoumon; Pyridines; Risk Factors; Stroke; Time Factors | 2012 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2015 |
Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
Topics: Action Potentials; Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pyrazoles; Pyridones; Registries; Rivaroxaban; Stroke; Time Factors; Treatment Outcome | 2016 |
[Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine].
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Middle Aged; Patient Discharge; Phenprocoumon; Retrospective Studies; Rivaroxaban; Vitamin K | 2016 |
The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Cryosurgery; Dabigatran; Female; Germany; Humans; Incidence; Inflammation Mediators; Male; Middle Aged; Phenprocoumon; Postoperative Complications; Pulmonary Veins; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2016 |
Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Automation, Laboratory; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Ischemic Attack, Transient; Male; Microfluidic Analytical Techniques; Microscopy, Fluorescence; Middle Aged; Phenprocoumon; Predictive Value of Tests; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Time Factors; Treatment Outcome; Whole Blood Coagulation Time | 2017 |
Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Cardiac Catheters; Cerebrovascular Disorders; Cryosurgery; Dabigatran; Drug Administration Schedule; Drug Monitoring; Equipment Design; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Postoperative Hemorrhage; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Vitamin K | 2017 |
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome | 2018 |
Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Case-Control Studies; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Clot Lysis Time; Heparin, Low-Molecular-Weight; Humans; Linear Models; Male; Middle Aged; Phenprocoumon; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Thromboplastin; Tissue Plasminogen Activator | 2018 |
Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Female; Germany; Humans; Male; Middle Aged; Phenprocoumon; Platelet Aggregation Inhibitors; Primary Health Care; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Young Adult | 2018 |
Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon in Geriatric and Non-Geriatric Patients with Non-Valvular Atrial Fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Geriatrics; Germany; Humans; Middle Aged; Phenprocoumon; Proportional Hazards Models; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Vitamin K | 2019 |